ARCHIVES

FDA advisors vote against recommending Johnson & Johnson’s Zarnestra for treatment of AML in the elderly.

This article is from The Cancer Letter archive.

Vol. 31 No. 18 | May 6, 2005

Download PDF Visit The Full Archive

Related Articles

Reviewers Found For Chronobiolgy

June 30, 1989

New Treatment For Malignant Glioma, IL13-PE38, Tested In Early Clinical Trials

December 28, 2001

In Brief: Murphy New ACS President, Robert McKenna Named President Elect Gehan Receives Gottlief Award

November 18, 1983

NCAB Approves New Grant Award Honoring Howard Temin

March 8, 1996

NIH Reconsiders Closing A Meeting Of Advisory Group

January 13, 1995

NCI Told To “Cut Out The Nonsense,” Adequately Fund Programs At Centers Required By Mandates

November 5, 1976